• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Deadline Approaching: Apply for the Fierce AI Innovation Awards

Biotech

Magnifying glass focusing on number 2026 with target icon on yellow background
Biotech

Despite headwinds, biotech industry charges forward behind M&A

Biotech’s effervescent activity has allowed it to overcome headwinds and sustain momentum, as the volume and value of M&A deals continue to increase.
Kevin Dunleavy Jun 9, 2026 12:41pm
rollercoaster ride theme park scary crazy

Parabilis ups planned IPO haul to record-setting $637M

Jun 9, 2026 10:22am
How AI is reshaping biopharma decision-making

How AI is reshaping biopharma decision-making

Brought to you by Clarivate
AlzeCure

Lilly licenses AlzeCure Alzheimer’s asset for $1B biobucks

Jun 9, 2026 10:16am
Managing complexity across biopharma modalities

Managing complexity across biopharma modalities

Brought to you by SK Pharmteco
AZ

ADA: AZ’s oral GLP-1 shows ‘competitive efficacy’ in phase 2

Jun 9, 2026 9:48am
Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings